SANDOMIGRAN

This brand name is authorized in Australia, Canada, Hong Kong, Netherlands, New Zealand, Turkey, South Africa

Active ingredients

The drug SANDOMIGRAN contains one active pharmaceutical ingredient (API):

1 Pizotifen UNII 99O99YVR4C - PIZOTYLINE MALATE

Pizotifen is a tricyclic (Benzocycloheptathiophene) compound possessing structural similarities to cyproheptadine and the tricyclic antidepressant drugs. Pharmacodynamic studies demonstrate pizotifen to have powerful antiserotonin and antitryptaminic properties, marked antihistaminic effects and some antagonistic activity against kinins. The prophylactic effect of pizotifen in migraine is associated with its ability to modify the humoral mechanisms of headache.

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SANDOMIGRAN Tablet	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CX01	Pizotifen	N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CX Other antimigraine preparations
Discover more medicines within N02CX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 3074T
Country: CA	Health Products and Food Branch	Identifier(s): 00511552
Country: HK	Department of Health Drug Office	Identifier(s): 01588
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 83542
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 817
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699504120608
Country: ZA	Health Products Regulatory Authority	Identifier(s): C/7.3/0112